Literature DB >> 10675786

Chronic methylphenidate treatment enhances water maze performance following traumatic brain injury in rats.

A E Kline1, H Q Yan, J Bao, D W Marion, C E Dixon.   

Abstract

Methylphenidate (MPH), a central nervous system stimulant with dopaminergic activity, facilitates neurobehavioral outcome following cortical suction ablation injury, but its potential efficacy following experimental traumatic brain injury (TBI) is unknown. Thus, beginning 24 h after controlled cortical impact injury or sham surgery, male Sprague-Dawley rats were injected (i.p.) once daily for 18 days with either MPH (5 mg/kg) or saline vehicle (VEH) and motor function assessed on post-operative days 1-4, followed by Morris water maze training to find a hidden platform on days 14-18. The MPH treatment regimen was ineffective in accelerating beam-balance or beam-walk recovery, but did significantly decrease swim latencies when compared to VEH-treated controls. The results are consistent with published studies showing improved outcome with MPH therapy. Furthermore, this positive finding with delayed treatment suggests that strategies that enhance catecholamine neurotransmission during the chronic post injury phase may be a useful adjunct in ameliorating some of the neurobehavioral sequelae following TBI in humans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10675786     DOI: 10.1016/s0304-3940(00)00797-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  40 in total

1.  Targeting Dopamine in Acute Traumatic Brain Injury.

Authors:  James W Bales; Anthony E Kline; Amy K Wagner; C Edward Dixon
Journal:  Open Drug Discov J       Date:  2010

Review 2.  Catecholaminergic based therapies for functional recovery after TBI.

Authors:  Nicole D Osier; C Edward Dixon
Journal:  Brain Res       Date:  2015-12-19       Impact factor: 3.252

3.  Differential effects of single versus multiple administrations of haloperidol and risperidone on functional outcome after experimental brain trauma.

Authors:  Anthony E Kline; Jaime L Massucci; Roos D Zafonte; C Edward Dixon; Judith R DeFeo; Emily H Rogers
Journal:  Crit Care Med       Date:  2007-03       Impact factor: 7.598

4.  Traumatic brain injury reduces striatal tyrosine hydroxylase activity and potassium-evoked dopamine release in rats.

Authors:  Samuel S Shin; Eric R Bray; Cathy Q Zhang; C Edward Dixon
Journal:  Brain Res       Date:  2010-11-01       Impact factor: 3.252

5.  Spontaneous recovery after controlled cortical impact injury is not impeded by intermittent administration of the antipsychotic drug risperidone.

Authors:  Lauren J Carlson; Gina C Bao; Sonya Besagar; Jacob B Leary; Hannah L Radabaugh; Corina O Bondi; Anthony E Kline
Journal:  Neurosci Lett       Date:  2018-06-06       Impact factor: 3.046

6.  Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury.

Authors:  Amy K Wagner; Laura L Drewencki; Xiangbai Chen; F Ryan Santos; Amina S Khan; Rashed Harun; Gonzalo E Torres; Adrian C Michael; C Edward Dixon
Journal:  J Neurochem       Date:  2008-12-10       Impact factor: 5.372

7.  Intermittent treatment with haloperidol or quetiapine does not disrupt motor and cognitive recovery after experimental brain trauma.

Authors:  Jillian J Weeks; Lauren J Carlson; Hannah L Radabaugh; Patricia B de la Tremblaye; Corina O Bondi; Anthony E Kline
Journal:  Behav Brain Res       Date:  2016-09-21       Impact factor: 3.332

8.  Intermittent Administration of Haloperidol after Cortical Impact Injury Neither Impedes Spontaneous Recovery Nor Attenuates the Efficacy of Environmental Enrichment.

Authors:  Gina C Bao; Isabel H Bleimeister; Lydia A Zimmerman; JoDy L Wellcome; Peter J Niesman; Hannah L Radabaugh; Corina O Bondi; Anthony E Kline
Journal:  J Neurotrauma       Date:  2019-01-09       Impact factor: 5.269

9.  Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury.

Authors:  Anthony E Kline; Ann N Hoffman; Jeffrey P Cheng; Ross D Zafonte; Jaime L Massucci
Journal:  Neurosci Lett       Date:  2008-10-25       Impact factor: 3.046

Review 10.  5-hydroxytryptamine1A (5-HT1A) receptor agonists: A decade of empirical evidence supports their use as an efficacious therapeutic strategy for brain trauma.

Authors:  Jeffrey P Cheng; Jacob B Leary; Aerin Sembhi; Clarice M Edwards; Corina O Bondi; Anthony E Kline
Journal:  Brain Res       Date:  2015-11-21       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.